総合バリュエーションレンジ · 保守的 2.45–2.6 / 妥当 3.45–4.05 / 楽観的 5.15–5.4。3.31 時点で 保守的レンジと妥当レンジの間。
レポート公開時 3.63（2026年8月1日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
沿革
近日公開このセクションは現在準備中です。近日公開予定です。
業界での地位
近日公開このセクションは現在準備中です。近日公開予定です。